Article
Chemistry, Multidisciplinary
Fan Wang, Yuqi Jiang, Luhai Wang, Yi Chen, Yu Zhang, Ming Ma
Summary: This study successfully prepared magnetic fluorescent nanoprobes targeted at CXCR4, which were used for the isolation and detection of drug-resistant acute myeloid leukemia cells. The probes demonstrated excellent targeting efficacy to CXCR4 overexpressed AML cells and could be magnetically isolated on a microfluidic chip.
Article
Pharmacology & Pharmacy
Catarina Roma-Rodrigues, Alexandra R. Fernandes, Pedro V. Baptista
Summary: Neoangiogenesis is associated with poor prognosis in cancer, including chronic myeloid leukemia (CML). The small GTP-binding protein Rab11a plays a crucial role in the neoangiogenic process in CML patients, by controlling exosome secretion and regulating vascular endothelial factor receptors. By downregulating Rab11a mRNA in CML cells, the angiogenic potential of exosomes can be reduced, offering a potential therapeutic approach for inhibiting tumor angiogenesis.
Article
Biochemistry & Molecular Biology
Raquel Alves, Ana Cristina Goncalves, Joana Jorge, Antonio M. Almeida, Ana Bela Sarmento-Ribeiro
Summary: This study evaluated the therapeutic potential of elacridar, a P-glycoprotein and BCRP inhibitor, in CML cell lines. The results showed that elacridar as monotherapy was not effective, but when combined with imatinib, it could overcome resistance. This provides a new treatment option for overcoming TKI resistance.
Article
Biochemistry & Molecular Biology
Giordana Feriotto, Paolo Marchetti, Riccardo Rondanin, Federico Tagliati, Serena Aguzzi, Simone Beninati, Fabio Casciano, Claudio Tabolacci, Carlo Mischiati
Summary: In this study, the bis-ketone moiety of curcumin (CUR) was replaced to obtain more stable derivatives 2 and 22. The evaluation of their chemical-physical characteristics and cell experiments showed that derivatives 2 and 22 had better bioavailability and stability than CUR, and exhibited significant cytotoxicity and pro-apoptotic effects on chronic myeloid leukemia (CML) cells. Moreover, derivative 22 was able to reverse drug resistance in CML cells resistant to imatinib (IM).
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Menghan Liu, Lin Yang, Xiaojun Liu, Ziyuan Nie, Xiaoyan Zhang, Yaqiong Lu, Yuxia Pan, Xingzhe Wang, Jianmin Luo
Summary: In this study, it was found that HNRNPH1 is upregulated in CML and correlated with disease progression. Knockdown of HNRNPH1 in CML cells inhibited cell proliferation, promoted apoptosis, and increased sensitivity to imatinib. The HNRNPH1-PTPN6-PI3K/AKT axis plays a critical role in CML tumorigenesis and targeting this pathway may represent a therapeutic approach for CML treatment.
FRONTIERS IN ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Emmanuel Pourcelot, Ghina El Samra, Pascal Mossuz, Jean-Marc Moulis
Summary: AML remains a disease with poor prognosis despite efforts to understand its molecular foundations and find effective treatments. In this study, we identified disturbed cellular iron homeostasis as a potential factor impacting therapeutic strategies targeting AML blasts.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Medicine, General & Internal
Jorge Cortes, Carolina Pavlovsky, Susanne Saussele
Summary: Tyrosine-kinase inhibitors have significantly altered the natural course of chronic myeloid leukaemia, allowing some patients to approach a near-normal life expectancy. Successful treatment requires understanding the patient's treatment goals, monitoring optimal response hallmarks, timely interventions, recognition of adverse events, and management of comorbidities.
Review
Oncology
Wonhyoung Seo, Prashanta Silwal, Ik-Chan Song, Eun-Kyeong Jo
Summary: In this review, the multifaceted functions of autophagy in AML were discussed, including its link to genetic alterations, potential prognostic predictors, and drivers of AML tumorigenesis. The crosstalk between autophagy and tumor cell metabolism and its impact on AML progression and treatment were also examined. Additionally, the potential therapeutics for AML, such as autophagy regulators, were described, along with their translation into clinical practice.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Giordana Feriotto, Federico Tagliati, Riccardo Giriolo, Fabio Casciano, Claudio Tabolacci, Simone Beninati, Mahmud Tareq Hassan Khan, Carlo Mischiati
Summary: Caffeic acid demonstrated anti-proliferative and apoptosis-inducing effects on chronic myeloid leukemia cells at micro-molar concentrations, by increasing the expression of cell cycle repressor genes. Additionally, it enhanced the anti-leukemic effect of imatinib, highlighting its nutraceutical potential in CML.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Cell & Tissue Engineering
Hanieh Mojtahedi, Niloufar Yazdanpanah, Nima Rezaei
Summary: CML is driven by the BCR-ABL1 oncoprotein, and TKI therapy has been successful. However, mechanisms leading to resistance and disease progression in CML LSCs call for targeted therapies to eradicate them.
STEM CELL RESEARCH & THERAPY
(2021)
Article
Materials Science, Biomaterials
Zhigang Fang, Yanling Sun, Chenlei Cai, Ruifang Fan, Rui Guo, Deming Xie
Summary: The study successfully prepared DPT nanoparticles for delivering DOX to improve chemotherapy efficacy on K562 leukemia cells, with an encapsulation efficiency of over 70% and enhanced targeting compared to DP nanoparticles.
INTERNATIONAL JOURNAL OF POLYMERIC MATERIALS AND POLYMERIC BIOMATERIALS
(2021)
Article
Biochemistry & Molecular Biology
Rachid Lahlil, Anne Aries, Maurice Scrofani, Celine Zanetti, Desline Hennequin, Bernard Drenou
Summary: Chronic myeloid leukemia (CML) is a clonal myeloproliferative disease characterized by the presence of the BCR-ABL fusion gene. Treatment with tyrosine kinase inhibitors (TKIs) such as imatinib mesylate (IM) has significantly improved clinical outcomes for CML patients, but IM resistance remains a major challenge. The cause of IM resistance in CML cells is unclear, but additional genetic alterations in leukemic stem cells (LSCs) are a common cause of relapse. A study found that a rare subpopulation of stem cells called very small embryonic-like stem cells (VSELs) in adult CML patients is resistant to IM and less sensitive to apoptosis compared to leukemic hematopoietic stem cells (HSCs). The expression levels of certain miRNAs are also affected in these IM-resistant VSELs, including miR-126 and miR-21, which are involved in LSC leukemia-initiating capacity and growth.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Biochemistry & Molecular Biology
Binoy Yohannan, Binsah George
Summary: This article provides a comprehensive summary of the current management of Lymphoid Blast Crisis (BC), which is one of the most feared complications of chronic myeloid leukemia (CML). The incidence of BC has significantly decreased in the BCR-ABL tyrosine kinase inhibitor era, but there is still a need for novel therapies to improve the clinical outcomes of patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
You Jiang, Shui-Yan Wu, Yan-Ling Chen, Zi-Mu Zhang, Yan-Fang Tao, Yi Xie, Xin-Mei Liao, Xiao-Lu Li, Gen Li, Di Wu, Hai-Rong Wang, Ran Zuo, Hai-Bo Cao, Jing-Jing Pan, Juan-Juan Yu, Si-Qi Jia, Zheng Zhang, Xin-Ran Chu, Yong-Ping Zhang, Chen-xi Feng, Jian-Wei Wang, Shao-Yan Hu, Zhi-Heng Li, Jian Pan, Fang Fang, Jun Lu
Summary: This study systematically explored the molecular characteristics of CEBPG in AML and identified CEBPG as a potential therapeutic target for AML patients. It was found that CEBPG promotes AML cell proliferation by activating EIF4EBP1, thus contributing to the progression of AML.
CANCER CELL INTERNATIONAL
(2021)
Article
Oncology
Yan-Hong Liu, Man Zhu, Pan-Pan Lei, Xiao-Yan Pan, Wei-Na Ma
Summary: The study revealed that the novel compound ND-09 inhibited CML cell growth by targeting BCR-ABL and altering its kinase activity, ultimately leading to growth arrest in CML cells.
Review
Pharmacology & Pharmacy
Fahima Dilnawaz, Sanjeeb Kumar Sahoo
DRUG DISCOVERY TODAY
(2015)
Review
Biochemistry & Molecular Biology
Fahima Dilnawaz
CURRENT MEDICINAL CHEMISTRY
(2019)
Review
Pharmacology & Pharmacy
Fahima Dilnawaz, Sarbari Acharya, Sanjeeb Kumar Sahoo
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2018)
Correction
Nanoscience & Nanotechnology
Abhalaxmi Singh, Fahima Dilnawaz, Sujeet Mewar, Uma Sharma, N. R. Jagannathan, Sanjeeb Kumar Sahoo
ACS APPLIED MATERIALS & INTERFACES
(2014)
Correction
Engineering, Biomedical
Fahima Dilnawaz, Abhalaxmi Singh, Sanjeeb Kumar Sahoo
ACTA BIOMATERIALIA
(2013)
Correction
Engineering, Biomedical
Fahima Dilnawaz, Abhalaxmi Singh, Sujeet Mewar, Uma Sharma, N. R. Jagannathan, Sanjeeb Kumar Sahoo
Article
Engineering, Biomedical
Fahima Dilnawaz, Abhalaxmi Singh, Sujeet Mewar, Uma Sharma, N. R. Jagannathan, Sanjeeb Kumar Sahoo
Article
Pharmacology & Pharmacy
Fahima Dilnawaz, Sanjeeb Kumar Sahoo
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
(2013)
Editorial Material
Biotechnology & Applied Microbiology
Deepika Singh, Fahima Dilnawaz, Sanjeeb Kumar Sahoo
Review
Biochemistry & Molecular Biology
Pratikshya Sa, Sanjeeb K. Sahoo, Fahima Dilnawaz
Summary: Cancer is a major global health challenge, and the tumor microenvironment plays a vital role in tumor progression and drug resistance. Targeting the tumor microenvironment is a promising approach to advance cancer nanomedicine. Recent progress in understanding the tumor microenvironment and developing responsive nanoparticles has improved pharmacokinetics and efficacy of nanomedicine in overcoming drug resistance. This review discusses the components of the tumor microenvironment and the role of nanomedicine in combating drug resistance.
CURRENT MEDICINAL CHEMISTRY
(2023)
Review
Biochemistry & Molecular Biology
Fahima Dilnawaz, Sarbari Acharya
Summary: Genome editing has emerged as a promising approach for treating complex diseases such as cancer. Delivery technologies utilizing viral vectors have shown some success in protein and nucleic acid delivery, but improvements are still needed in terms of efficiency, tissue targeting abilities, and toxicity. Nanotechnology offers a potential solution by providing nano-vehicles that can overcome these challenges and serve as safe and efficient genome editing tools for cancer therapy.
CURRENT MEDICINAL CHEMISTRY
(2023)
Article
Nanoscience & Nanotechnology
Fahima Dilnawaz, Sanjeeb K. Sahoo
ACS APPLIED NANO MATERIALS
(2018)
Review
Biochemistry & Molecular Biology
Fahima Dilnawaz
CURRENT MEDICINAL CHEMISTRY
(2017)
Article
Nanoscience & Nanotechnology
Fahima Dilnawaz, Abhalaxmi Singh, Sanjeeb K. Sahoo
NANOTECHNOLOGY IN HEALTH CARE
(2012)
